A detailed history of Caisse De Depot Et Placement Du Quebec transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Caisse De Depot Et Placement Du Quebec holds 371,969 shares of VRTX stock, worth $152 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
371,969
Previous 555,665 33.06%
Holding current value
$152 Million
Previous $260 Million 33.58%
% of portfolio
0.34%
Previous 0.63%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $84.5 Million - $92.9 Million
-183,696 Reduced 33.06%
371,969 $173 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $118 Million - $145 Million
-299,444 Reduced 35.02%
555,665 $260 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $20.9 Million - $22.9 Million
51,383 Added 6.39%
855,109 $357 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $4.22 Million - $5.05 Million
-12,298 Reduced 1.51%
803,726 $327 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $18.3 Million - $19.6 Million
-54,052 Reduced 6.21%
816,024 $284 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $45 Million - $50.4 Million
-143,147 Reduced 14.13%
870,076 $306 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $29.2 Million - $33.3 Million
103,202 Added 11.34%
1,013,223 $319 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $50.1 Million - $56.3 Million
-175,199 Reduced 16.14%
910,021 $263 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $53.1 Million - $59.2 Million
-193,874 Reduced 15.16%
1,085,220 $314 Million
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $24.6 Million - $30.6 Million
104,486 Added 8.9%
1,279,094 $360 Million
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $11.9 Million - $14.1 Million
-53,900 Reduced 4.39%
1,174,608 $307 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $47.2 Million - $59.6 Million
-266,708 Reduced 17.84%
1,228,508 $270 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $261 Million - $292 Million
1,438,039 Added 2515.07%
1,495,216 $271 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $9.09 Million - $10.7 Million
48,476 Added 557.13%
57,177 $11.5 Million
Q1 2021

May 14, 2021

BUY
$207.02 - $241.31 $1.43 Million - $1.67 Million
6,925 Added 389.92%
8,701 $1.87 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $254,415 - $339,314
-1,229 Reduced 40.9%
1,776 $420,000
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $153,390 - $181,860
-600 Reduced 16.64%
3,005 $818,000
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $8,568 - $11,240
-38 Reduced 1.04%
3,605 $1.05 Million
Q1 2020

May 14, 2020

SELL
$199.77 - $247.81 $951,304 - $1.18 Million
-4,762 Reduced 56.66%
3,643 $867,000
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $960,249 - $1.29 Million
5,760 Added 217.77%
8,405 $1.84 Million
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $109,711 - $123,479
-660 Reduced 19.97%
2,645 $448,000
Q2 2019

Aug 09, 2019

SELL
$164.61 - $190.37 $329,220 - $380,740
-2,000 Reduced 37.7%
3,305 $606,000
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $65,491 - $77,880
-400 Reduced 7.01%
5,305 $976,000
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $75,955 - $96,105
500 Added 9.61%
5,705 $945,000
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $33,546 - $38,548
-200 Reduced 3.7%
5,205 $1 Million
Q2 2018

Aug 13, 2018

BUY
$145.72 - $169.96 $14,572 - $16,996
100 Added 1.89%
5,405 $919,000
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $14.3 Million - $16.8 Million
-94,600 Reduced 94.69%
5,305 $865,000
Q4 2017

Feb 13, 2018

BUY
$137.28 - $155.55 $12.6 Million - $14.3 Million
92,000 Added 1163.82%
99,905 $15 Million
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $1.17 Million - $1.28 Million
7,905
7,905 $1.21 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Caisse De Depot Et Placement Du Quebec Portfolio

Follow Caisse De Depot Et Placement Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caisse De Depot Et Placement Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Caisse De Depot Et Placement Du Quebec with notifications on news.